Author/Creator: van Langenberg, Daniel - British Library Electronic Legal Deposit Catalogue-Journal Issues and Articles Search Results

Author/Creator van Langenberg, Daniel

1. Faecal microbiota transplantation for recurrent Clostridioides difficile infection: an Australian experience − effective, safe, yet room for improvement. Issue 1 (11th February 2021)

Authors:: Chauhan, Ayushi; Apostolov, Ross; van Langenberg, Daniel; Garg, Mayur
Journal:: Internal medicine journal
Issue:: Volume 51:Issue 1(2021)
Page Start:: 106
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗

2. Letter: rationalising aminosalicylates in inflammatory bowel disease. Issue 10 (21st October 2020)

Authors:: Nicolaides, Steven; Vasudevan, Abhinav; van Langenberg, Daniel
Journal:: Alimentary pharmacology & therapeutics
Issue:: Volume 52:Issue 10(2020)
Page Start:: 1619
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗

3. Low-dose thiopurine with allopurinol co-therapy overcomes thiopurine intolerance and allows thiopurine continuation in inflammatory bowel disease. Issue 7 (July 2018)

Authors:: Vasudevan, Abhinav; Beswick, Lauren; Friedman, Antony B.; Moltzen, Alicia; Haridy, James; Raghunath, Ajay; Sparrow, Miles; van Langenberg, Daniel
Journal:: Digestive and liver disease
Issue:: Volume 50:Issue 7(2018)
Page Start:: 682
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗

4. Poor predictive value of breath hydrogen response for probiotic effects in IBS. Issue 12 (December 2015)

Authors:: Yao, Chu K; Barrett, Jacqueline S; Philpott, Hamish; Chung, Alvin R T; van Langenberg, Daniel; Garg, Mayur; Gibson, Peter R
Journal:: Journal of gastroenterology and hepatology
Issue:: Volume 30:Issue 12(2015:Dec.)
Page Start:: 1731
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗

5. Real-World Effectiveness of Ustekinumab Dose Intensification in Crohn's Disease. Issue 6 (11th February 2021)

Authors:: Srinivasan, Ashish; van Langenberg, Daniel; De Cruz, Peter
Journal:: Inflammatory bowel diseases
Issue:: Volume 27:Issue 6(2021)
Page Start:: e69
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗

6. Real-World Effectiveness of Ustekinumab Dose Intensification in Crohn's Disease. Issue 6 (17th May 2021)

Authors:: Srinivasan, Ashish; van Langenberg, Daniel; De Cruz, Peter
Journal:: Inflammatory bowel diseases
Issue:: Volume 27:Issue 6(2021)
Page Start:
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗

7. Switching Australian patients with moderate to severe inflammatory bowel disease from originator to biosimilar infliximab: a multicentre, parallel cohort study. Issue 3 (17th October 2020)

Authors:: Haifer, Craig; Srinivasan, Ashish; An, Yoon‐Kyo; Picardo, Sherman; van Langenberg, Daniel; Menon, Shankar; Begun, Jakob; Ghaly, Simon; Thin, Lena
Journal:: Medical journal of Australia
Issue:: Volume 214:Issue 3(2021)
Page Start:: 128
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗

8. Systematic review and meta-analysis: evaluating response to empiric anti-TNF dose intensification for secondary loss of response in Crohn's disease. (February 2022)

Authors:: Srinivasan, Ashish; Gilmore, Robert; van Langenberg, Daniel; De Cruz, Peter
Journal:: Therapeutic advances in gastroenterology
Issue:: Volume 15(2022)
Page Start:
Record Type:: Journal Article
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗